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Background
The most common form of chronic arthritis is osteoarthritis (OA) with prevalence as high as 80% after 
age 75 (Arden and Nevitt, 2006). The incidence of OA is expected to increase as the population ages, 
increasing the socioeconomic burden of OA. Despite the signiﬁ  cant burden of this disease, no drug has 
been identiﬁ  ed that can effectively modify disease progression (Moskowitz and Hooper, 2005; Abadie 
et al. 2004). However, slowing disease progress and improvement in quality of life may be achieved 
by behavioral modiﬁ  cations, such as weight loss and exercise. Many patients with early OA will prog-
ress to disability and joint replacement. Physical examination and radiographic studies are relatively 
poor means for detecting disease early or predicting progression. Therefore, identiﬁ  cation of factors to 
facilitate early OA diagnosis and prognosis is a major focus of current OA research (Lohmander and 
Felson, 2004; Lohmander, 2004; Garnero and Delmas, 2003).
Considerable intellectual and ﬁ  nancial resources are currently being invested into this biomarker 
development effort worldwide in the hope that biomarkers will help in the following ways: i) to diagnose 
OA prior to the stage when loss of articular cartilage can be measured on a radiograph, ii) to identify 
patients with increased risk of progression, iii) to monitor effectiveness of therapeutic interventions, and 
iv) to select patients for clinical trials of new drugs. To this end, numerous potential OA biomarkers 
have emerged over the last decade (Moskowitz and Hooper, 2005). These biomarkers comprise a diverse 
group of molecules derived from all components of the joint. Moreover, studies of these molecules 
have provided valuable insights into cartilage pathobiology (Poole, 2003).
An imbalance in cartilage synthesis and degradation is central to the development of OA (Guilak 
et al. 2004; Lippiello et al. 1977; Malemud et al. 2003). Therefore, products of cartilage metabolism 
have been explored as potential candidate biomarkers for OA. Cartilage is composed of two major 
proteins, aggrecan, and type II collagen, in addition to many less abundant proteins such as decorin, 
ﬁ  bromodulin, cartilage oligomeric matrix protein (COMP), cartilage intermediate layer protein (CILP), 
proline arginine-rich end leucine-rich protein (PRELP), various minor collagens, link protein, ﬁ  bro-
nectin, and the glycosaminoglycan- hyaluronan (Saxne, 2006). Potential OA related biomarkers can 
originate both within and outside of joint tissues (Table 1). The focus of this review is type II collagen, 
the most abundant protein component of cartilage and a molecule that has yielded a wealth of potential 
OA-related biomarkers.
Many different type II collagen epitopes have been described as potential OA biomarkers (Table 2). 
Interestingly, many of these epitopes can reﬂ  ect different biological processes even though they originate 
from the same molecule. For instance, collagen provides epitopes indicative of both degradative or 
catabolic events, and synthetic or anabolic events. Simultaneous assessment of both collagen degrada-
tion and synthesis in a patient is a particularly promising approach for diagnosing and determining risk 
of OA progression (Poole, 2003). Thus, type II collagen serves as a useful and instructive paradigm of 
the biomarker development process. In conjunction with the presentation of the human clinical evidence 
available for each of the collagen biomarkers, we make use of the newly proposed BIPED classiﬁ  cation 
scheme put forth by the Osteoarthritis Biomarkers Network (Bauer et al. 2006). The proposed algorithm 
classiﬁ  es markers into ﬁ  ve categories for the purpose of applying a common biomarker vocabulary across 
investigators, their laboratories and potentially across ﬁ  elds, and to facilitate the design of biomarker 
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validation studies.The BIPED acronym represents 
the following categories: burden of disease, inves-
tigative, prognostic, efﬁ  cacy of intervention, and 
diagnostic; when possible, we have related the 
outcomes of the available relevant human clinical 
data to one or more of these categories.
Collagen Biomarkers
Collagen Synthesis and Degradation 
Type II collagen is a homotrimer of a1(II) chains. 
These undergo hydroxylation, interchain disulﬁ  de 
bonding, and triple helix formation (winding from 
the C- toward the N-terminus). The molecule is 
then secreted to the extracellular matrix of carti-
lage. There are two procollagen variants of type 
II collagen derived by alternative splicing: procol-
lagen IIA possessing a cysteine-rich von Willibrand 
factor C-like domain in the N-terminal propeptide 
(PIIANP) (O’Leary et al. 2004), and procollagen 
IIB lacking this cysteine-rich domain within the 
amino propeptide (McAlinden et al. 2005). The 
procollagen IIA variant is expressed during fetal 
development and during OA in what is believed 
to be an attempted repair response to cartilage 
degradation (Aigner et al. 1999; Salminen et al. 
2001), procollagen IIB is expressed in normal 
adult cartilage. These procollagen forms undergo 
processing to the mature form with release of N- 
and C- terminal propeptides that are indicative of 
the amount of newly synthesized collagen. Groups 
of mature collagen ﬁ  brils associate in regular stag-
gered arrays and undergo cross-linking to form 
larger ﬁ  brils and ﬁ  bers (Gelse et al. 2003).
Type II collagen is cleaved by collagenases 
known as metalloproteinases (MMPs); MMP-1, 
8, and 13 are thought to be particularly important. 
Collagenase mediated cleavage results in two 
fragments: a ¾ length fragment (also referred to as 
TC
A) and a ¼ length fragment (TC
B). This prote-
olysis causes a loss of type II collagen epitopes to 
Table 1. Potential Arthritis Biomarkers.
Type II Collagen Related Epitopes (see Table 2) 
Aggrecan Related Epitopes
     Chondroitin sulfate epitopes 2B6, 3B3 and 846
     Keratan Sulfate
     Uronic acid 
   Total glycosaminoglycan (dimethylmethylene blue binding)
Hyaluronan
Link Protein
Cartilage Oligomeric Matrix Protein
Cartilage Intermediate Layer Protein
Proline Arginine-Rich End Leucine-Rich Protein
Decorin 
Matrix Metalloproteinases
Cytokine Proﬁ  les
C-Reactive Protein
Fibromodulin
Fibronectin Fragments
Human Cartilage Glycoprotein 39 (YKL-40)
Glucosyl-Galactosyl-Pyridinoline 
Peripheral Blood Mononuclear Cell RNA ExpressionProﬁ  les
Bone Turnover Biomarkers
     NTXI
     CTXI
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Table 2. Currently available biomarkers of type II collagen degradation and synthesis. 
Biomarker Name
a AA Sequence  AA
Residues
b
Specificity
c Body 
Fluid or 
Tissue
d
Ab
e BIPED
Classification
f
References Related to 
Assay Development  
Collagen
Degradation 
Cleavage
Neoepitopes
Col2-1/4N1 LAGQRG 907-912  Not
specified 
C p(Fab)2 I (Billinghurst et al., 
1997)  
Col2-1/4N2 QRGIVG 910-915  CII  C p(Fab)2 I (Billinghurst et al., 
1997) 
C1,2C
 (COL2-3/4Cshort)
GPP(OH)GPQG  899-906  CI and CII  S, SF, C  p P (combined 
with C2C or 
CPII), D 
(Billinghurst et al., 
1997) 
C2C
(COL2-3/4Clong 
mono)
EGPP(OH)GPQ
G
898-906 CII  in 
humans 
S,SF,U m P  (combined 
with C1,2C 
Or CPII), E,D 
(Poole et al., 2004) 
uTIINE (5109 and 
9A4  ELISA; 5109 
capture in LC-
MS/MS format) 
GEPGDDGPS/G
PPGPQG;
ARGDSGPPGR
AGEPGLQGPA
GPPGEKGEPG
DDGPSGAEGP
PGPQG
888-
896/899-
906; 862-
906
CII U m/m; 
m/LC-
MS/M
S
B,P,E,D (Otterness  et  al.,  1999, 
Downs et al., 2001, 
Burgeson and Nimni, 
1992, Hellio Le 
Graverand et al., 2006) 
Denaturation 
Neoepitopes
COL2-3/4m  APGEDGRPGP
PG
511-522  CII, CXI  C, S  m  D (Hollander et al., 1994) 
Coll 2-1 
Coll 2-1 NO2
HRGYPGLDG 220-228  CII  S,U  p P,D  (Deberg et al., 2002, 
Henrotin et al., 2004) 
Helix-II
∞ ERGETGPP(OH
GTS
754-764  CII  U p P,D  (Charni et al., 2005) 
AH12 GAPGPQGFQG
NPGEPGEPGVS
147-167 CII  C p I  (Croucher  and 
Hollander, 1999) 
AH8 GPPGPPGKPG
DDGEAGKPGK
A
174-194 CII  C m  and 
p
I (Croucher  and
Hollander, 1999) 
AH9 GPP(OH)GP 
RGRSGETGPA
GPP(OH)GNP(O
H)
1116-
1136
CII C p I (Croucher  and 
Hollander, 1999) 
CII CNBr9.7 
(18:6:D6 and 
14:7:D8 ELISA) 
Epitope within 
CNBr
9.7/GPQGPRGD
KGEAGEP 
1028-
1151/104
1-1055 
CII/CI, CII, 
CIII, CV 
SF m/m  D (Barrach et al., 1996, 
Elsaid and Chichester, 
2006) 
Telopeptide
Epitopes
col2CTx
 g
CTX-II (Urine 
CartiLaps and 
preclinical serum 
assay) 
g
(R)EKGPDP 1160-
1166
CII cross-
links
C,S,P(ED
TA),SF,U 
m, m/m  B,P,E,D  (Eyre, 1991, Christgau 
et al., 2001, Oestergaard 
et al., 2006, Matyas et 
al., 2004, Eyre, 1989) 
Collagen
Synthesis
CPII
PIICP
(chondrocalcin) 
Sequence within 
C-propeptide: 
DQAAGGLR 
Q…DIGPVCFL
1173-
1418 (of 
procollag
en IIB in 
Figure 1a 
or 1242-
1487 in 
procollag
en IIA in 
Figure 
1b) 
CII S,SF, C  p
p/p
B,P,E,D (Van der Rest et al., 
1986, Sugiyama et al., 
2003, Mansson et al., 
1995, Shinmei et al., 
1993) 
PIIANP  QEAGSCVQDG
QRYNDKDVW
KPE
PCRICVCDTGT
VLCDDIICEDV
KDCLSPEIPFG
ECCPICPTDLA
TAS
29-97 (of 
procollag
en IIA in 
figure 1b)  
CII S (not 
plasma) 
p P (combined 
with
uCTXII),E,D 
(Oganesian et al., 1997, 
O'Leary et al., 2004) 
)
(Continued)
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body ﬂ  uids wherein they can indicate the amount of 
degradation of collagen. The ability to monitor and 
slow or reverse this process has important clinical 
and therapeutic implications because extensive 
degradation of mature cross-linked type II collagen 
ﬁ  bers is considered to be a critical and perhaps 
irreversible stage in joint destruction (Billinghurst 
et al. 1997; Nelson et al. 1998).
Collagen Degradation Biomarkers
Type II collagen is possibly the ideal marker of 
cartilage degradation. First, it is relatively speciﬁ  c 
to articular cartilage, although it is also found in 
other cartilages as well as the vitreous humor
of the eye and the nucleus pulposus of lumbar 
discs (Burgeson and Nimni, 1992; Elsaid and 
Chichester, 2006). Second, type II collagen is the 
most abundant protein in cartilage, representing 
15–25% of the wet weight, 50% of the dry weight, 
and 90–95% of the total collagen content. Third, 
type II collagen turnover is normally very slow, 
with a biological half-life estimated to be 117 
years in adult cartilage (Verzijl et al. 2000), thus 
pathological turnover is readily detected above 
background metabolism.  Furthermore, many 
assays have been produced to measure the prod-
ucts of type II collagen metabolism in the serum, 
synovial ﬂ  uid, and urine of animal models of 
arthritis as well as in humans. The type II collagen 
biomarkers indicative of degradation fall into 
three groups according to the localization of the 
particular epitope within the collagen molecule: 
cleavage neoepitopes localized to the collagenase 
cleavage site; denaturation neoepitopes localized 
to the triple-helical domain and made accessible to 
the detection reagents by unwinding of the triple 
helix; and epitopes localized to the mature ends or 
telopeptides of the molecule (Table 2).
Cleavage neoepitopes
The process of collagen cleavage and denaturation 
of the triple helical molecule exposes certain 
protein sequences, termed neoepitopes, within 
the collagen molecule.  These neoepitopes can 
be measured and correlated with the amount of 
cartilage degradation.
Col 2¼– N1 and ¼N2: Billinghurst and Poole 
were the ﬁ  rst to report on the use of antibodies 
to detect neoepitopes of collagen generated by 
collagenase cleavage (Billinghurst et al. 1997). 
COL2-1/4N1 is an amino-terminal neoepitope on 
the shorter fragment (TC
B) of collagen, and COL2-
1/4N2 is generated by a secondary collagenase 
cleavage resulting in an amino-terminal neoepitope 
lacking 3 amino acid residues of the TC
B fragment. 
Little else has been published on the use of these 
markers for OA diagnosis, progression, or response 
to therapy.
C2C and C1,2C: Neoepitopes identiﬁ  ed at the 
C-terminus of the ¾ length fragment, include C2C 
and C1,2C. C1,2C is a carboxy-terminal cleavage 
neoepitope on the ¾ fragment of collagen. The 
name ‘C1,2’ signiﬁ  es that this neoepitope is not 
speciﬁ  c for collagen type II but is also generated 
upon collagenase cleavage of type I collagen, 
exposing the 5 amino-terminal residues on the ¾ 
fragment that are identical for both collagens type I 
and II. C1,2C is the product of secondary cleavage 
of the C2C product (described below) and is
resistant to further degradation. Mean (SD) serum 
values for non-arthritic controls are available in 
the literature only for females (314 + 119 ng/ml) 
a The biomarker name is the usual one in the literature and does not discriminate if it applies to an antibody, an epitope, or an assay  name. 
b Categories are based on localization of an epitope in the type II collagen molecule and residue numbering is based on the human type II 
collagen sequence, P024588 in UniProtKB/Swiss sequence shown in Figure 1a:
-Cleavage neoepitopes localized to the collagenase cleavage site between Gly
906 and Leu
907
-Denaturation neoepitopes localized to the triple-helical domain
-Epitopes localized to the telopeptides
-Collagen synthesis epitopes localized to the N-propeptide domain (AA 26–112) or C-propeptide domain (AA 1173–1418).
c CII = type II collagen; CI = type I collagen; CIX = type IX collagen.
d The table shows human body ﬂ  uid or tissue for which the application of the assay is documented in the literature: S = serum; SF = syno-
vial ﬂ  uid; U = urine; C = cartilage explant.
e m - monoclonal antibody (mAb), p - polyclonal antiserum, m/m - a sandwich of two mAbs, LC-MS/MS - liquid chromatography with mass 
spectroscopy.
f Provisional BIPED classiﬁ  cation categories based on Bauer et al. (Bauer et al. 2006): B = burden of disease; I = investigative; P = prog-
nostic; E = efﬁ  cacy of intervention; D = diagnostic marker. 
g The antibodies to Col2CTx and CTX-II are speciﬁ  c for a peptide that happens to be present in the cross-linked structure in human body 
ﬂ  uids but the cross-link is not a part of the epitope.
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(Haima, 2005). This neoepitope is also referred 
to as COL2-3/4Cshort, signifying the length of the 
epitope, not the length of the fragment on which the 
epitope is located (Poole et al. 2004). This assay, 
which is ELISA based and commercially available 
(IBEX, Montreal, Quebec), can be used on serum, 
synovial ﬂ  uid, and cartilage.
As a diagnostic marker, C1,2C has been shown 
to be elevated in cartilage from patients with OA 
compared to controls (17 pmole/mg cartilage 
compared to 7 pmole/mg; p value 0.0002) (Billin-
ghurst et al. 1997). In a cartilage explant system, 
cleavage of type II collagen by collagenase was 
signiﬁ  cantly increased in OA cartilage samples, 
generating higher levels of C1,2C in vitro from 
OA cartilage; this elevation could be blocked 
by collagenase inhibitors (Dahlberg et al. 2000). 
Collagenase inhibitors can also inhibit the loss 
of this epitope from bovine cartilage explants in 
response to IL-1 (Billinghurst et al. 2000). In a 
population-based sample in humans, serum C1,2C 
has been associated with incident radiographic 
knee OA (Jordan et al. 2004b) and is higher in 
African Americans than Caucasians (Jordan et al. 
2004a).
C2C is measured by a commercially available 
ELISA (IBEX, Montreal, Quebec). The epitope is 
located at the C-terminus of the ¾ length fragment. 
The problem of speciﬁ  city for type II collagen 
posed by C1,2C was solved by lengthening the C1,2C 
epitope sequence by three amino acid residues 
(GGEGPP(OH)GPQG) where E corresponds to 
a residue speciﬁ  c to human type II collagen, and 
the tandem GG represents a spacer, thought to be 
important for recapitulating a speciﬁ  c conforma-
tion of the native epitope upon release from the 
triple helix. This neoepitope, originally designated 
COL2-3/4Clong, is now known as C2C (Poole et al. 
2004). Hydroxylation of  P902 within this epitope is 
essential for C2C immunoreactivity while hydrox-
ylation at other sites within this epitope abolish 
C2C immunoreactivity (Poole et al. 2004). There-
fore, subtle species differences in hydroxylation of 
this sequence may dramatically impact the ability 
to detect this epitope with the anti-C2C monoclonal 
antibody. As with C1,2C, mean serum values are 
available in the literature only for non-arthritic 
females (58 + 28 ng/ml) (Haima, 2005). This assay 
can be used on serum, urine, or synovial ﬂ  uid in 
humans (Fraser et al. 2003; Cibere et al. 2005), and 
animals (Kojima et al. 2001; Song et al. 1999; Chu 
et al. 2002), although the speciﬁ  city of the assay 
for type II collagen in animals is in question due 
to the fact that residue E899 of the C2C epitope, 
corresponding to human type II collagen, is a D in 
monkeys, rodents, including guinea pigs, horses, 
dogs and chickens. Levels of this neoepitope were 
high a few weeks after an experimentally induced 
inﬂ  ammatory arthritis (collagen induced arthritis, 
CIA) or OA (Song et al. 1999; Kojima et al. 2001; 
Chu et al. 2002; Kojima, 2004; Billinghurst et al. 
2001). This neoepitope has declined in association 
with reduced destruction of joint cartilage in a rat 
model of CIA treated with collagenase inhibitors 
(Song et al. 1999). In a transgenic mouse model 
of OA, C2C was elevated before the onset of clini-
cally apparent cartilage lesions (El-Maadawy et al. 
2003 ). These animal studies establish the utility 
of this assay for detection and quantiﬁ  cation of 
cartilage degradation. 
A signiﬁ  cant correlation has been observed 
for serum C2C and cartilage volume by magnetic 
resonance imaging in patients with symptomatic 
knee OA (King et al. 2004). C2C has also been 
associated with incident radiographic knee OA 
(Jordan et al. 2004b).  Treatment of rheumatoid 
arthritis patients with infliximab and metho-
trexate resulted in reduction of serum C2C levels 
compared to levels in placebo treated patients and 
correlated with symptomatic improvement in the 
ASPIRE trial (Visvanathan et al. 2004). Compared 
to placebo, treatment of ankylosing spondylitis 
patients with etanercept resulted in suppressed 
serum C2C in a manner that correlated with the 
decline in sedimentation rate (ESR) and C-reac-
tive protein levels (Maksymowych et al. 2005). 
However, no difference in urinary or serum C2C, 
C1,2C, or their ratio were observed between groups 
following treatment for 6 months with glucosamine 
or placebo for knee OA (Cibere et al. 2005).
The combination of C2C with C1,2C may 
improve the ability to predict which patients will 
have progressive OA. In a study of 209 patients 
with established knee OA, higher ratios of C1,2C/
C2C were observed for OA progressors compared 
to non-progressors over 18 months (Cerejo et al. 
2002; Sharma et al. 2004). They speculated that 
the higher ratio in progressors was due to increased 
secondary cleavage of the long (¾) fragment of 
type II collagen. They have reported an increased 
odds of OA progression for the highest tertiles of 
C2C:CPII ratios (Odds Ratio 3.15), and C1,2C:CPII 
ratios (Odds Ratio 1.79). In a cohort of 330 indi-
viduals in a population based study, the C2C/C1,2C 
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ratio was also associated with knee OA progression 
(p = 0.06) (Jordan et al. 2004b).  Overall, these 
studies support the designation of C2C, or C2C in 
combination with C1,2C or CPII, for the diagnosis 
and prognosis of OA and for monitoring the efﬁ  -
cacy of some therapeutic interventions for OA. 
uTIINE:  The urinary Type II Collagen 
NeoEpitope (uTIINE) is detected by a sandwich 
ELISA with speciﬁ  city for type II collagen degra-
dation. The detection monoclonal antibody (mAb) 
used in this assay, 9A4, binds the type II collagen 
neoepitope generated at the new C-terminus on the 
collagen ¾ fragment following collagen cleavage 
and detects the same collagen neoepitope as C1,2C 
(Otterness et al. 1999).  Speciﬁ  city of the assay 
for type II collagen is achieved with the capture 
mAb 5109 (Otterness et al. 1999; Downs et al. 
2001), which is only capable of binding type II 
collagen in monomeric as opposed to native triple 
helical collagen conformation. Three amino acid 
residues (GAE) separate the epitopes for these two 
mAbs, preventing steric competition. Recently a 
liquid chromatography-mass spectrometry/mass 
spectroscopy (LC-MS/MS) format of the assay 
has been developed that relies on immunoafﬁ  nity 
capture with the 5109 antibody.  This assay has 
led to the demonstration that a 45-mer peptide is 
the most abundant uTIINE species in the urine 
and synovial ﬂ  uid (Hellio Le Graverand et al. 
2006). Of note, this assay is not useful in rabbits 
and guinea pigs because of sequence differences 
in the epitope recognized by the antibody 5109. 
In principle, an epitope present in serum has to 
be present also in synovial ﬂ  uid, and an epitope 
present in urine has to be present also in serum and 
synovial ﬂ  uid. However, in the case of uTIINE, 
this urinary epitope is not found in serum at the 
level of detection of the assay (0.169 ng/ml, 0.05 
nM). This has been ascribed to lack of reabsorp-
tion into the plasma after glomerular ﬁ  ltration due 
to the size and chemical properties (highly polar 
and acidic) of this peptide (Hellio Le Graverand 
et al. 2006).
Early investigative work showed that measur-
able quantities of uTIINE were detectable in 9/10 
OA patients but only 2/10 controls (Downs et al. 
2001). In this study, the uTIINE concentrations 
in OA patients were almost three-fold higher 
than the 2 controls with the measurable levels 
(312 pM and 123 pM respectively) (Downs et al. 
2001). These data support the use of this ELISA 
for the diagnosis of OA.  OA and RA severity 
have also been assessed with uTIINE and levels 
were found to correlate with and predict disease 
status in RA (Saltarelli et al. 1999; Woodworth
et al. 1999). Levels of uTIINE do not vary diurnally 
and decreased in response to initiation of metho-
trexate therapy in newly diagnosed rheumatoid 
arthritis patients (Pickering et al. 2000; Saltarelli 
et al. 2000). Using the new LC-MS/MS format in 
a cross-sectional study, uTIINE was ~50% higher 
in individuals with symptomatic radiographic OA 
of the hip or knee compared to individuals with 
asymptomatic radiographic knee OA, and indi-
viduals over age 55 years without radiographic 
OA (Pickering et al. 2004).  Again using this 
newer assay format, serial uTIINE concentrations 
reﬂ  ected concurrent joint space narrowing in a 
trial evaluating the effect of doxycycline for knee 
OA (Hellio Le Graverand et al. 2006) suggesting a 
possible role as a burden of disease marker. Levels 
of uTIINE have also been shown to reﬂ  ect cartilage 
degradation in relapsing polychondritis (Kraus
et al. 2003), a severe autoimmune disorder asso-
ciated with hyaline cartilage destruction. In this 
study, uTIINE levels were elevated prior to treat-
ment, fell with anti-tumor necrosis alpha therapy 
in concert with symptomatic improvement, and 
then rose again after therapy was discontinued. 
These studies provide a rationale for the use of 
this ELISA to follow type II collagen degradation 
in response to therapy.
Collagen denaturation epitopes 
After the initial cleavage of the collagen triple helix 
by collagenase, the helix can denature into the 
monomeric a1(II) chains. Denaturation epitopes 
are “unmasked” and made accessible following the 
unwinding of a1 chains from the usual conforma-
tional restriction in the triple-helix.
Col2-3/4m: Dodge and Poole used denatured 
(unwound) a-chains of cyanogens bromide 
(CNBr)-derived peptides of bovine tropocollagen 
type II as immunogens (a1(II)CB11 - residues 
254–533, and a1(II)CB8 - residues 533–682 of 
Figure 1a) to prepare polyclonal antiserum R181 
(Dodge and Poole, 1989). These CNBr peptides 
were localized to the ﬁ  rst (N-terminal) half of the 
helical domain and did not contain the collagenase 
cleavage site. The antiserum did not react with 
native type II collagen or collagens of other types 
and was used in immunohistochemical studies 
(Dodge and Poole, 1989; Dodge et al. 1991). One 
of ﬁ  ve hydrophilic domains from the CNBr-derived 
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Figure 1a. Amino acid sequence in a1(II) chain of human procollagen type IIB (COL2A1_HUMAN, P02458, UniProtKB/Swiss). Numbering 
of amino acids in this ﬁ  gure (and throughout the whole text of this review) is consistent with numbering in the source given above and may 
not correspond to numbering in a particular reference. Numbering used here includes N-terminal signal peptide and N-propeptide, and does 
not include the alternatively spliced block of 69 amino acids in the N-propeptide (which is shown in Figure 1b).  Each number corresponds 
to the last one of ten amino acids under it.
- Tandems Proline/Hydroxyproline and Lysine/Hydroxylysine are not distinguished and are represented by the same letter (P and K, re-
spectively).
- Positions of cross-links are color-coded and underlined (K
121, 239, 1061, and 1162).  
- The telopeptides (in red lettering) and epitopes discussed in this review is as follows:
113–131 N-terminal non-helical domain (N-terminal telopeptide)
1146–1172 C-terminal non-helical domain (C-terminal telopeptide)
132–1145 Triple-helical domain    
1173–1418 Carboxy-terminal propeptide domain
26–112 Amino-terminal propeptide domain
10         20         30         40         50         60
MIRLGAPQSL VLLTLLVAAV LRCQGQDVRQ PGPKGQKGEP GDIKDIVGPK GPPGPQGPAG
        70         80         90        100        110        120
EQGPRGDRGD KGEKGAPGPR GRDGEPGTLG NPGPPGPPGP PGPPGLGGNF AAQMAGGFDE
130        140        150        160        170        180
KAGGAQLGVM QGPMGPMGPR GPPGPAGAPG PQGFQGNPGE PGEPGVSGPM GPRGPPGPPG
       190        200        210        220        230        240
KPGDDGEAGK PGKAGERGPP GPQGARGFPG TPGLPGVKGH RGYPGLDGAK GEAGAPGVKG
       250        260        270        280        290        300
ESGSPGENGS PGPMGPRGLP GERGRTGPAG AAGARGNDGQ PGPAGPPGPV GPAGGPGFPG
       310        320        330        340        350        360
APGAKGEAGP TGARGPEGAQ GPRGEPGTPG SPGPAGASGN PGTDGIPGAK GSAGAPGIAG
       370        380        390        400        410        420
APGFPGPRGP PDPQGATGPL GPKGQTGKPG IAGFKGEQGP KGEPGPAGPQ GAPGPAGEEG
       430        440        450        460        470        480
KRGARGEPGG VGPIGPPGER GAPGNRGFPG QDGLAGPKGA PGERGPSGLA GPKGANGDPG
       490        500        510        520        530        540
RPGEPGLPGA RGLTGRPGDA GPQGKVGPSG APGEDGRPGP PGPQGARGQP GVMGFPGPKG
       550        560        570        580        590        600
ANGEPGKAGE KGLPGAPGLR GLPGKDGETG AEGPPGPAGP AGERGEQGAP GPSGFQGLPG
       610        620        630        640        650        660
PPGPPGEGGK PGDQGVPGEA GAPGLVGPRG ERGFPGERGS PGAQGLQGPR GLPGTPGTDG
       670        680        690        700        710        720
PKGASGPAGP PGAQGPPGLQ GMPGERGAAG IAGPKGDRGD VGEKGPEGAP GKDGGRGLTG
       730        740        750        760        770        780
PIGPPGPAGA NGEKGEVGPP GPAGSAGARG APGERGETGP PGTSGIAGPP GADGQPGAKG
       790        800        810        820        830        840
EQGEAGQKGD AGAPGPQGPS GAPGPQGPTG VTGPKGARGA QGPPGATGFP GAAGRVGPPG
       850        860        870        880        890        900
SNGNPGPPGP PGPSGKDGPK GARGDSGPPG RAGEPGLQGP AGPPGEKGEP GDDGPSGAEG
↓910        920        930        940        950        960
PPGPQGLAGQ RGIVGLPGQR GERGFPGLPG PSGEPGQQGA PGASGDRGPP GPVGPPGLTG
       970        980        990       1000       1010       1020
PAGEPGREGS PGADGPPGRD GAAGVKGDRG ETGAVGAPGA PGPPGSPGPA GPTGKQGDRG
      1030       1040       1050       1060       1070       1080
EAGAQGPMGP SGPAGARGIQ GPQGPRGDKG EAGEPGERGL KGHRGFTGLQ GLPGPPGPSG
      1090       1100       1110       1120       1130       1140
DQGASGPAGP SGPRGPPGPV GPSGKDGANG IPGPIGPPGP RGRSGETGPA GPPGNPGPPG
      1150       1160       1170       1180       1190       1200
PPGPPGPGID MSAFAGLGPR EKGPDPLQYM RADQAAGGLR QHDAEVDATL KSLNNQIESI
      1210       1220       1230       1240       1250       1260
RSPEGSRKNP ARTCRDLKLC HPEWKSGDYW IDPNQGCTLD AMKVFCNMET GETCVYPNPA
      1270       1280       1290       1300       1310       1320
NVPKKNWWSS KSKEKKHIWF GETINGGFHF SYGDDNLAPN TANVQMTFLR LLSTEGSQNI
      1330       1340       1350       1360       1370       1380
TYHCKNSIAY LDEAAGNLKK ALLIQGSNDV EIRAEGNSRF TYTALKDGCT KHTGKWGKTV
      1390       1400       1410
IEYRSQKTSR LPIIDIAPMD IGGPEQEFGV DIGPVCFL 
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Figure 1b. Amino acid sequence of a1(II) chain of human procollagen type IIA (UniProtKB/TrEMBL entry Q14047) 
29–97 The alternatively spliced 69 amino acids of the amino-terminal propeptide domain. 
10         20         30         40         50         60
MIRLGAPQSL VLLTLLVAAV LRCQGQDVQE AGSCVQDGQR YNDKDVWKPE PCRICVCDTG
        70         80         90        100        110        120
TVLCDDIICE DVKDCLSPEI PFGECCPICP TDLATASGQP GPKGQKGEPG DIKDIVGPKG
       130        140        150        160        170        180
PPGPQGPAGE QGPRGDRGDK GEKGAPGPRG RDGEPGTPGN PGPPGPPGPP GPPGLGGNFA
       190        200        210        220        230        240
AQMAGGFDEK AGGAQLGVMQ GPMGPMGPRG PPGPAGAPGP QGFQGNPGEP GEPGVSGPMG
       250        260        270        280        290        300
PRGPPGPPGK PGDDGEAGKP GKAGERGPPG PQGARGFPGT PGLPGVKGHR GYPGLDGAKG
       310        320        330        340        350        360
EAGAPGVKGE SGSPGENGSP GPMGPRGLPG ERGRTGPAGA AGARGNDGQP GPAGPPGPVG
       370        380        390        400        410        420
PAGGPGFPGA PGAKGEAGPT GARGPEGAQG PRGEPGTPGS PGPAGASGNP GTDGIPGAKG
       430        440        450        460        470        480
SAGAPGIAGA PGFPGPRGPP GPQGATGPLG PKGQTGEPGI AGFKGEQGPK GEPGPAGPQG
       490        500        510        520        530        540
APGPAGEEGK RGARGEPGGV GPIGPPGERG APGNRGFPGQ DGLAGPKGAP GERGPSGLAG
       550        560        570        580        590        600
PKGANGDPGR PGEPGLPGAR GLTGRPGDAG PQGKVGPSGA PGEDGRPGPP GPQGARGQPG
       610        620        630        640        650        660
VMGFPGPKGA NGEPGKAGEK GLPGAPGLRG LPGKDGETGA AGPPGPAGPA GERGEQGAPG
       670        680        690        700        710        720
PSGFQGLPGP PGPPGEGGKP GDQGVPGEAG APGLVGPRGE RGFPGERGSP GAQGLQGPRG
       730        740        750        760        770        780
LPGTPGTDGP KGASGPAGPP GAQGPPGLQG MPGERGAAGI AGPKGDRGDV GEKGPEGAPG
       790        800        810        820        830        840
KDGGRGLTGP IGPPGPAGAN GEKGEVGPPG PAGSAGARGA PGERGETGPP GPAGFAGPPG
       850        860        870        880        890        900
ADGQPGAKGE QGEAGQKGDA GAPGPQGPSG APGPQGPTGV TGPKGARGAQ GPPGATGFPG
       910        920        930        940        950        960
AAGRVGPPGS NGNPGPPGPP GPSGKDGPKG ARGDSGPPGR AGEPGLQGPA GPPGEKGEPG
       970        980        990       1000       1010       1020
DDGPSGAEGP PGPQGLAGQR GIVGLPGQRG ERGFPGLPGP SGEPGKQGAP GASGDRGPPG
      1030       1040       1050       1060       1070       1080
PVGPPGLTGP AGEPGREGSP GADGPPGRDG AAGVKGDRGE TGAVGAPGAP GPPGSPGPAG
      1090       1100       1110       1120       1130       1140
PTGKQGDRGE AGAQGPMGPS GPAGARGIQG PQGPRGDKGE AGEPGERGLK GHRGFTGLQG
      1150       1160       1170       1180       1190       1200
LPGPPGPSGD QGASGPAGPS GPRGPPGPVG PSGKDGANGI PGPIGPPGPR GRSGETGPAG
      1210       1220       1230       1240       1250       1260
PPGNPGPPGP PGPPGPGIDM SAFAGLGPRE KGPDPLQYMR ADQAAGGLRQ HDAEVDATLK
      1270       1280       1290       1300       1310       1320
SLNNQIESIR SPEGSRKNPA RTCRDLKLCH PEWKSGDYWI DPNQGCTLDA MKVFCNMETG
      1330       1340       1350       1360       1370       1380
ETCVYPNPAN VPKKNWWSSK SKEKKHIWFG ETINGGFHFS YGDDNLAPNT ANVQMTFLRL
      1390       1400       1410       1420       1430       1440
LSTEGSQNIT YHCKNSIAYL DEAAGNLKKA LLIQGSNDVE IRAEGNSRFT YTALKDGCTK
      1450       1460       1470       1480
HTGKWGKTVI EYRSQKTSRL PIIDIAPMDI GGPEQEFGVD IGPVCFL 
peptide, a1(II)CB11, was subsequently synthe-
sized and used to prepare a monoclonal antibody 
(mAb) designated COL2-3/4m, referring to the 
fact that the epitope is localized to the larger of the 
two collagenase cleavage fragments of collagen 
(Hollander et al. 1994). The antibody does not 
interact with native type II collagen but there is 
activity against homologous sequence in type XI 
collagen [a3(XI) chain], which is present in very 
small amounts in cartilage. This mAb has also 
been used preferentially in immunohistochemistry 
studies demonstrating damage of type II collagen 
in human articular cartilage in OA (Hollander
et al. 1994; Hollander et al. 1995).  Increased 
levels of COL2-3/4m are found in superﬁ  cial 
layers of OA cartilage early in the disease process 
and increased levels in deeper layers as the disease 
progresses (Hollander et al. 1995).
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Investigational use of this marker has demon-
strated its utility for identifying cartilage damage 
in rodent models of arthritis.  COL2-3/4m was 
elevated in the knees of experimental mouse 
models of arthritis, particularly in ﬁ  brillated areas 
compared to non-arthritic control knees (Stoop
et al. 1999b). This elevation began within 3 days 
of experimental arthritis and remained elevated at 
28 days. The same investigators found that COL2-
3/4m was able to identify cartilage denaturation in 
a mouse model of spontaneous OA as well as an 
injury model of experimental OA in rats (Stoop
et al. 1999a; Stoop et al. 2001). In human studies, 
this assay has shown potential as a diagnostic 
marker by differentiating OA from non-OA with 6-
fold more denatured type II collagen in OA samples 
versus controls (Hollander et al. 1994). Data are 
lacking as of yet to support the classiﬁ  cation of 
this marker as a burden of disease, prognostic, or 
efﬁ  cacy of intervention marker. 
Coll 2-1 and Coll 2-1 NO2: Henroitin et al. 
prepared rabbit antisera to a denaturation neoepi-
tope, Coll 2-1, that corresponds to a peptide local-
ized to another part of the helical domain of type 
II collagen (Deberg et al. 2002; Henrotin et al. 
2004). Since the sequence contains tyrosine, an 
analogous competition ELISA was developed for 
the nitrated tyrosine form of the peptide (Coll 2-1 
NO2). Using antisera (D3 and D37) derived from 
rabbits, the mean serum levels of these epitopes in 
adults aged 20–65 years were 125.13 + 3.71 nmol/l 
(Coll 2-1), and 0.16 + 0.08 nmol/l (Coll 2-1 NO2), 
and did not vary by age. They demonstrated higher 
levels of Coll 2-1 NO2 in females under the age of 
45 compared with men (Henrotin et al. 2004).
Coll 2-1 is signiﬁ  cantly elevated in OA patients 
compared to control (267.45 + 26.42 nmol/l versus 
126.78 + 6.61 nmol/l) (Henrotin et al. 2004).
Additionally, the ratio of Coll 2-1 NO2 to Coll 
2-1 was shown to differentiate RA from OA with 
a 1.6 fold higher ratio in RA compared to OA
(p < 0.05) (Deberg et al. 2005a). Higher levels of 
Coll 2-1 and Coll 2-1 NO2 in the urine have been 
shown to predict progression of radiographic joint 
space narrowing over one year (Henrotin et al. 2004; 
Deberg et al. 2005b). However, no association was 
found between these marker levels and radiographic 
grade of severity of joint disease. Therefore, these 
markers are not yet able to claim utility in burden 
of disease assessments. Data are not available to 
assess their ability to serve as indicators of the 
efﬁ  cacy of therapeutic interventions.
HELIX-II: HELIX-II is detected in urine by 
a competitive ELISA using polyclonal antisera. 
This degradation epitope of the helical region of 
type II collagen was recently quantiﬁ  ed in patients 
with OA, RA, and Paget’s disease, and healthy 
controls (Charni et al. 2005).  The HELIX-II 
ELISA showed no significant cross-reactivity 
with human intact or denatured type II collagen, 
with similar peptides from human type I or type 
III collagens, or with elongated or shortened 
HELIX-II peptides, indicating that the HELIX-II 
ELISA recognizes a neoepitope from the alpha 1 
chain of type II collagen that is unmasked upon 
collagen denaturation (Charni et al. 2005).  As 
a diagnostic marker, HELIX-II concentrations 
were signiﬁ  cantly higher in patients with OA (by 
56%, P < 0.0001) and RA (by 123%, P < 0.0001) 
(Charni et al. 2005) compared to healthy age- and 
sex-matched controls. In the same study, elevated 
HELIX-II was a risk factor for radiographic 
damage in RA, implying utility as a prognostic 
marker. This effect was found to be independent 
of C-reactive protein, baseline damage, and uCTX-
II level (described below). Data on response to 
therapy are not available for this marker.
AH12, AH8 and AH9:  The antibodies 
AH12 and AH8 were developed and applied in a
sandwich  ELISA  patented by Hollander and Croucher 
(Hollander and Croucher, 1998). This assay detects 
two sequential epitopes separated by six amino
acid residues in the amino-terminal portion of the 
triple helical domain of type II collagen, made 
accessible by unwinding of the triple helix. This 
assay is investigative as no published data exist 
on its utility in diagnosis, prognosis, or effect of 
therapy in humans.  A third antibody, AH9, has 
been developed to a carboxy-terminal sequence 
within the triple helical domain of type II collagen. 
Together with AH9, the sandwich ELISA assay has 
been used to monitor the release of amino- and 
carboxy-terminal fragments of type II collagen from 
cartilage explants treated with IL-1alpha (Croucher 
and Hollander, 1999). Although they were readily 
able to detect AH12-AH8 reactive epitopes, they 
were unable to detect AH9 reactive epitopes. They 
suggested that that the amino-terminus is relatively 
resistant to further degradation while the carboxy-
terminus is labile after the helical domain of type 
II collagen is denatured (Croucher and Hollander, 
1999). These results demonstrate that the helical 
region of type II collagen is not uniform in its 
susceptibility to proteolysis. They concluded that 
Biomarker Insights 2006:170
Kraus et al.
domain is contributed from a different molecule
of collagen from that of the telopeptides (which
can hypothetically originate from two a chains of 
one molecule). The cross-link probably explains 
the stability and survival of the epitope from carti-
lage via blood to urine. Eyre’s group has devel-
oped several mAbs to these peptide epitopes (Atley
et al. 1998) including mAb 10F2 (Fernandes
et al. 2003), and mAb 2B4 (Eyre et al. 2004), 
enabling these cross-linked telopeptides to be 
detected by ELISA in body ﬂ  uids (Eyre, 1995).
Only investigative data are available on mAb 
10F2 (Fernandes et al. 2003).  Synovial fluid 
Col2CTx by ELISA (monoclonal antibody 2B4) 
correlates with the severity of histological OA 
in the canine (Matyas et al. 2004) and rabbit 
(Lindhorst et al. 2005) meniscectomy models of 
OA. ELISA with mAb 2B4 has also been used 
to analyze sera in familial arthritides (Moskowitz
et al. 1998; Christgau et al. 2001), and has demon-
strated high levels of Col2CTx in synovial ﬂ  uid of 
OA patients and patients after joint injury (Lohm-
ander et al. 2003).  Mean (SD) Col2CTx levels 
by 2B4 ELISA were also higher in patients with 
generalized knee and hand OA (51.9 + 20.7 ng/mg 
Cr), than in patients with single joint knee OA
(36.6 + 8.8 ng/mg Cr), which in turn was higher 
than levels in healthy controls (42.4 + 15.2 ng/mg 
Cr), thus supporting a role as a burden of disease 
marker (Atley et al. 2000). Amino-terminal telo-
peptides of type II collagen (Col2NTx) have not 
been found in body ﬂ  uids, suggesting they are 
degraded in vivo all the way to free hydroxylysyl-
pyridinoline.
CTX-II is identical to neoepitope Col2CTx 
described above, found at the C-terminus of the 
¼ length fragment of cleaved type II collagen. 
It is measured with commercially available kits 
(Nordic Bioscience, Herlev, Denmark) by ELISA 
in urine under the name Urine CartiLaps (Christgau 
et al. 2001), and more recently in sera. The urine 
and serum assays may potentially be measuring 
slightly different biochemical epitopes. The urine 
assay is a competitive ELISA which likely detects 
monomeric and dimeric CTX-II epitopes, while 
the serum assay is based on binding of two iden-
tical monoclonal antibodies in a sandwich ELISA 
which likely detects solely the cross-linked dimeric 
CTX-II (Christgau et al. 2001). The monoclonal 
antibodies (F4601 and F2603) forming the basis 
of these assays rely upon the C-terminal proline 
of the target sequence (EKGPDP) for immunore-
this fact has important implications for the choice 
of epitopes that are likely to be good markers of 
damage to cartilage collagen.
CII CNBr9.7: Barrach and Chichester et al. 
have developed a sandwich ELISA assay speciﬁ  c 
for CNBr9.7, a cyanogen bromide peptide in the 
¼ length cleavage fragment of type II collagen 
(Elsaid and Chichester, 2006). The capture anti-
body of this assay (18:6:D6) is speciﬁ  c to type II 
collagen while the detection antibody (14:7:D8) 
reacts to homologous sequence within types I, II, 
II and V collagen, although the authors also report 
some reactivity of both antibodies to sequences 
within CNBr11 in the ¾ length fragment of type II 
collagen (residues 254–533 of Figure 1a) (Elsaid 
and Chichester, 2006).  They have character-
ized levels of CII CNBr9.7 in the synovial ﬂ  uid 
of patients after acute knee injury or with OA
and RA (Barrach et al. 1996; Elsaid et al. 2003), 
and in the synovial fluid of rabbits following 
meniscectomy (Felice et al. 1999).  Synovial 
ﬂ  uid concentrations of the CII epitope increased 
with severity of articular cartilage degradation 
(Barrach et al. 1996). Interestingly, the CII peptide 
concentrations were highest in synovial ﬂ  uid from
patients with acute knee injury (mean 0.94 ng/ml) 
compared to synovial ﬂ  uid from patients with OA
(mean 0.13 ng/ml), RA (mean 0.17 ng/ml), or 
synovial ﬂ  uid from normal knees obtained post-
mortem (undetectable at < 50 ng/ml) (Elsaid
et al. 2003).
Collagen telopeptides 
Col2CTx and CTXII: Eyre was the ﬁ  rst to describe 
cross-links in telopeptides of fibril-forming
collagens type I, II and III (Eyre, 1989, Eyre, 
1991).  The structure of cross-linked peptides 
that originate from the C-terminal telopeptides 
of type II collagen is shown in Figure 2. Many 
variations of this basic structure can be isolated 
from body ﬂ  uids. For example, the cross-linked 
peptides can be longer or shorter by 1–3 amino 
acid residues, e.g. Glu-Hyl-Gly-Pro-Asp-Pro 
(EKGPDP) or Glu-Hyl-Gly-Pro-Asp-Pro-Leu 
(EKGPDPL), or Val-Hyl (VK).  The hydroxyl 
group of the 3-hydroxypyridinium cross-link can 
also be glycosylated.  Col2CTx is a composite 
term given by Eyre, et al. to describe several 
protease-generated neoepitopes originating from 
the C-telopeptides of the a1 chains of type II 
collagen ﬁ  brils.  It is assumed that the cross-
linked peptide originating from the triple helical 
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activity (Christgau et al. 2001; Oestergaard et al. 
2006). Normal urinary values differ signiﬁ  cantly 
by age and gender, with mean urinary values 
as follows (ng/mmol creatinine):  females 299;
peri-premenopausal females 168; peri-postmeno-
pausal females 318; males 278 (Haima, 2005; 
Mouritzen et al. 2003). This assay probably has 
the most abundant data supporting its use as an 
arthritis biomarker.  This epitope is elevated: in 
vitro in human OA explant cultures (Roy-Beaudry 
et al. 2003); in vivo in the serum in the rat collagen-
induced arthritis model (Ishikawa et al. 2004; De 
Ceuninck et al. 2003), in the synovial ﬂ  uid of the 
rat collagen-induced arthritis model (Oestergaard 
et al. 2006); and in the serum and synovial ﬂ  uid
of rats after intra-articular monoidoacetate injection 
(Oestergaard et al. 2006). The study by De Ceun-
inck, et al. also showed that CTX-II responded to 
collagenase inhibition (De Ceuninck et al. 2003). 
In addition to this investigational work, Jung,
et al. showed elevated uCTX-II in both RA and 
OA human subjects compared to control. In this 
study, OA patients had a three-fold higher CTX-
II level (527ng/mmol) compared to unaffected 
controls (190ng/mmol, p < 0.001) suggesting the 
utility of CTXII as a diagnostic OA biomarker 
(Jung et al. 2004).
CTX-II may also be useful as a disease burden 
marker and a prognostic marker. As an indication 
of degree of cartilage damage, CTX-II has been 
shown to correlate with degree of joint destruc-
tion (Christgau et al. 2001; Garnero et al. 2003; 
Garnero et al. 2001). Reijman, et al. showed that 
higher baseline CTX-II level correlated with risk 
of progression over a six year period in a cohort of 
237 knee and 123 hip OA subjects (Reijman et al. 
2004). Several studies suggest that CTX-II also 
has value in efﬁ  cacy of therapy assessments. In 
a prospective study comparing patients with knee 
OA ﬂ  are treated with rofecoxib versus placebo, 
Figure 2.  The sequence of the cross-linked Col2CTx epitope.  The crosslinked structure of this telopeptide biomarker, indicative of type II 
collagen degradation, enables it to survive to urine. The cross-link designated as Hyl-Hyl-Hyl is hydroxylysylpyridinoline.  
Collagen Sequence   Location  of  Sequence
       Glu-Hyl-Gly-Pro-Asp   α1(II) C-telopeptide 
          | 
Glu-Hyl-Gly-Pro-Asp   α1(II) C-telopeptide 
          | 
Gly-Val-Hyl      α1(II) triple-helical domain 
uCTX-II levels were 18% lower (p = 0.0003) in 
the treatment group compared to the placebo group, 
although the possibility cannot be ruled out that the 
drug decreased renal excretion of CTX-II (Gineyts 
E, 2004).  Similar effects were observed with 
ibuprofen (Gineyts et al. 2004). Additionally, in 
contrast to placebo, adalimumab has been shown 
to decrease uCTX-II levels in patients with RA 
(17.3% decrease, p < 0.01) (Garnero P, 2004). 
Finally, Landewe and colleagues demonstrated a 
decrease in uCTX-II levels in RA patients after 
3 months of treatment with disease modifying
anti-rheumatic drug (DMARD) therapy.  In 
this study, combination DMARD therapy with 
prednisone, sulfasalazine, and methotrexate 
decreased uCTX-II by 36% compared to 17% for 
sulfasalazine alone over 3 months. This decline in 
uCTX-II at 3 months predicted long term (5 year) 
improvement in radiographic outcome (Landewe 
et al. 2004).
Collagen Synthesis Biomarkers
Damage to cartilage also causes the chondrocyte 
to produce new type II collagen. This is secreted 
as a procollagen molecule that must undergo post-
translational modiﬁ  cation. As described above, the 
released amino- and carboxy-terminal propeptide 
protein fragments can be used to measure collagen 
synthesis (Hotta et al. 2005; Shinmei et al. 1993; 
Rousseau et al. 2004a).
CPII: CPII is measured with a commercially 
available ELISA (IBEX, Montreal, Quebec), and 
in other formats (Shinmei et al. 1993) and reﬂ  ects 
carboxy-terminal type II collagen propeptides 
in serum, synovial ﬂ  uid, and cartilage extracts. 
The CPII assay correlates directly with collagen 
synthesis (Nelson et al. 1998). Reported normal 
mean (SD) values for women are 217 + 60 ng/ml 
(Haima, 2005). CPII varies signiﬁ  cantly by gender 
with men having higher values than women (mean 
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lnCPII 5.49 in men, 5.36 in women) (Jordan et al. 
2004a). CPII immunoreactivity of OA cartilage 
is markedly elevated  (7.6-fold) although this 
does not appear to be reﬂ  ected in an increase of 
this epitope in the serum of OA patients (Nelson
et al. 1998). However, in RA sera, CPII is elevated 
in both rapidly and slowly progressive disease 
(Mansson et al. 1995). The elevation of serum CPII 
found in RA subjects could help differentiate RA 
from OA (Mansson et al. 1995). Using a sandwich 
ELISA format based on polyclonal antibodies, this 
epitope has been demonstrated to be elevated in 
the synovial ﬂ  uid in patients with OA, RA, and 
traumatic arthritis (Shinmei et al. 1993), and in 
the synovial ﬂ  uid of individuals with varus knee 
alignment or obesity, suggesting that mechanical 
stress stimulates chondrocytes to increase collagen 
synthesis (Kobayashi et al. 2000).  The authors 
concluded that CPII level in synovial ﬂ  uid is a 
marker of early OA due to mechanical risk factors. 
Additional studies support the notion that CPII is 
elevated in relation to body mass index and mechan-
ical stress (Kobayashi et al. 1997; Kobayashi
et al. 2002). Taken together, these data suggest that 
CPII may be useful for detecting early alterations 
of cartilage metabolism and cartilage damage.
Synovial ﬂ  uid CPII may also be useful for deter-
mining disease stage and those at risk for progres-
sion of OA. In a study by Lohmander et al. CPII 
levels were compared among healthy controls, knee 
injury subjects, and those with post-traumatic knee 
OA (Lohmander et al. 1996). In this study, levels 
of CPII were elevated shortly after knee injury and 
peaked within 1–4 years. Levels were 2–4 times 
higher in the OA and injury groups compared with 
control. Importantly, levels peaked well before 
radiographic OA was noted.  Only in patients 
with advanced disease did the CPII levels begin 
to drop. Correlation of CPII levels with severity 
of OA suggests its potential as a burden of disease
marker (Kobayashi et al. 1997). Synovial ﬂ  uid 
concentrations of the same collagen C-propep-
tide fragment in another commercially available
format (Teizin KK, Osaka, Japan), called PIICP,
has been shown to be predictive of radiographic 
knee OA in a four year prospective study (Sugiyama
et al. 2003).  In a study of ankylosing spon-
dylitis patients, CPII levels were found to be 
elevated and declined in response to inﬂ  iximab
treatment, suggesting that CPII may be useful 
as an efficacy of intervention biomarker
(Kim, 2004; Kim et al. 2005).
PIIANP:  Type IIA procollagen contains an 
additional 69 amino acid cysteine-rich domain in 
the N-propeptide that binds bone morphogenetic 
protein 2 and that has been hypothesized to play 
a role in chondrogenesis (Zhu et al. 1999). Anti-
sera to this sequence were initially developed to 
localize type IIA procollagen in embryonic tissues 
(Oganesian et al. 1997).  This reagent has been 
made available in a commercially available ELISA 
(Linco Research, St Charles, MO) to detect the 
N-terminal cleavage product of procollagen IIA 
in sera. PIIANP is indicative of type II collagen 
synthesis (Rousseau et al. 2004a). As a diagnostic 
marker, serum PIIANP is decreased in OA patients 
compared to controls, as was also noted with 
CPII (Garnero et al. 2002, Rousseau et al. 2004b; 
Rousseau et al. 2004a). Serum levels of PIIANP 
are lower in OA compared with RA patients. No 
data are available on the utility of PIIANP as a 
marker of disease burden. One study comparing 
OA to RA suggested that prednisone therapy in RA 
increased PIIANP levels compared to non-treated 
controls (15.0 + 2.4 versus 13.5 + 2.4 ng/ml, P < 
0.05) (Rousseau et al. 2004b). This suggests the
possible utility as an efficacy of intervention 
biomarker.
As noted previously, the use of a combination 
of biomarkers is a promising approach to the diag-
nosis, prediction of progression, and response to 
therapy, of various forms of arthritis. For instance, 
PIIANP has been combined with CTX-II to predict 
progression of radiographic knee OA (Garnero
et al. 2002).  An uncoupling index (decreased 
PIIANP and increased CTX-II) provided the 
greatest discriminatory capacity between OA and 
controls. Subjects with higher baseline uncoupling 
indices were more likely to have radiographic 
progression and pain one year later. The combina-
tion of low PIIANP (more than one SD below the 
mean of the controls), and a high CTX-II (more 
than one SD above the mean of the controls) was 
associated with an 8-fold more rapid progression of 
radiographic joint damage. The authors concluded 
that the combination of these markers was useful 
for detecting knee OA patients at highest risk for 
rapid progression.
Conclusions
Although much progress has been made both 
developing and validating type II collagen neoepi-
topes for arthritis applications, many unanswered
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questions remain. Do different assays in a category 
measure the same biological process or do they 
differ in their ability to correlate with incident or 
progressive joint disease? What threshold level of 
collagen degradation or synthesis in a particular 
joint is required to impact serum or urine concen-
trations? Since joints vary dramatically in size and 
rates of cartilage metabolism, how much epitope 
is contributed by a particular joint to body ﬂ  uids? 
What are the clearance rates of these collagen 
biomarkers from joints and the systemic circula-
tion? Do anti-arthritic drugs alter renal or hepatic 
clearance of a marker and thus confound interpre-
tation of drug effects on joint tissue metabolism? 
Do subtle variations of an epitope (e.g. post-trans-
lational modiﬁ  cations, differences in the length or 
amino acid content) lead to a difference in what is 
measured in the serum compared to the urine that can 
provide meaningful clinical insights? Additional 
problems arise when considering how to evaluate 
the ability of a biomarker to predict a meaningful 
clinical outcome. For example, what “gold stan-
dard” endpoint is to be used, radiographic change 
(plain ﬁ  lms, magnetic resonance imaging, other 
imaging modality) or patient symptoms, to evaluate 
the performance of the biomarker? The limitations 
of the so-called “gold standard” outcomes are well 
known and are part of the motivation to develop 
molecular biomarkers in the ﬁ  rst place.
It is also very important that additional 
efforts are made to better understand what exact 
biochemical species we are measuring in complex 
biological ﬂ  uids such as urine, serum and synovial 
ﬂ  uid. Assays that work very well under deﬁ  ned 
laboratory conditions may lose some or all of their 
speciﬁ  city when attempting to measure very low 
levels of speciﬁ  c epitopes in complex biological 
backgrounds. It is also important to understand 
potential sequence differences in species that 
may lead to variations in afﬁ  nity and speciﬁ  city 
of a particular assay. Newer methods in use and 
development, for instance the uTIINE assay, that 
involves immunocapture followed by mass spec-
troscopy, may provide more precise quantiﬁ  cation 
of a speciﬁ  c epitope.
Despite these many questions and cautionary 
notes, it is apparent that numerous useful and 
promising biomarkers, in various stages of devel-
opment, are currently available, even just consid-
ering this single protein, type II collagen. Since 
individual biomarkers have various limitations, 
it is likely that combining biomarkers will be the 
most effective means of diagnosing arthritis early, 
as well as to assess burden of disease, determine 
efﬁ  cacy of therapy, and predict which patients will 
have progressive disease. It seems probable that 
a clinical proﬁ  le will be assessed in future that 
includes family history, body habitus, joint injury, 
patient symptoms, radiographs, and biomarkers, to 
determine a patients risk proﬁ  le and help the physi-
cian diagnose and manage arthritis at the earliest 
stage possible.
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